The risk of thrombosis in essential thrombocythemia and polycythemia vera

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 10, 2002, Pages 16-21

  Pearson, Thomas C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKING; CLONOGENESIS; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS;

EID: 0036307706     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70148-6     Document Type: Review

References (41)

1. Incidence and risk factors for thrombic complications in a historical cohort of 100 patients with essential thrombocythemia
2. Major vascular complications in essential thrombocythemia: A study of predictive factors in a series of 148 patients
3. 9/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
4. 9/L
5. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
6. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis
7. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
8. Long-term use of anagrelide in young patients with essential thrombocythemia
9. Aspirin in essential thrombocythemia: Status quo and quo vadis
10. Neurologic and visual symptoms in essential thrombocythemia: Efficacy of low-dose aspirin
11. Hemostatic complications and role of aspirin in myeloproliferative disorders: Result of long term follow up of 394 patients
12. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: A rationale for the use of low-dose aspirin as an antithrombotic agent
13. Correlation of thrombosis with increased platelet turnover in thrombocytosis
14. Megakaryocytic and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications
15. The correlation of spontaneous erythroid and megakaryocytic colony formation and abnormal platelet function tests with the risk of arterial thrombosis in essential thrombocythaemia
16. Prediction of outcome and complications in patients with idiopathic thrombocytosis by endogenous erythroid colony assay
17. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis
18. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
19. Patients with essential thrombocythemia and clonal hemopoiesis detected by X-inactivation patterns are at high risk for thrombotic complication
20. Polycythemia vera: The natural history of 1213 patients followed for 20 years
21. Haemorheological considerations in the pathogenesis of vascular occlusive events in polycythaemia vera
22. Vascular occlusion episodes and venous hematocrit in primary proliferative polycythaemia
23. Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analysis of prospective studies of coronary heart disease
24. Hemoglobin and the risk of cerebral infarction: The Framingham study
25. Importance of the hematocrit as a risk factor in cerebral infarction
26. Effect of haematocrit on carotid stenosis and cerebral infarction
27. Erythromelalgia and vascular complications in polycythemia vera
28. The course and complications of idiopathic erythrocytosis
29. Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
30. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group
31. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera
32. Management of polycythemia vera with hydroxyurea
33. 32P between 1969 and 1981
34. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
35. Polycythaemia vera in young people: An analysis of 58 cases diagnosed before 40 years
36. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors
37. Evaluation of risk factors for thrombosis in patients with essential thrombocythaemia
38. In essential thrombocythemia the mutations V Leiden, prothrombin and methylene-tetrahydrofolate reductase are not risk factors for thromboembolic disease
39. Association of splanchnic vein thrombosis with hereditary 20210 G/A prothrombin genotype in chronic myeloproliferative disorders
40. Homocysteine and reactive oxygen species in polycythemia vera and essential thrombocythemia
41. Homocysteine levels in patients with myeloproliferative disorders